<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908788</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00232-53</org_study_id>
    <nct_id>NCT03908788</nct_id>
  </id_info>
  <brief_title>Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy</brief_title>
  <acronym>EmutRAS</acronym>
  <official_title>Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With Metastatic Colorectal Cancer During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The analysis of circulating DNA (Deoxyribonucleic acid) to identify potential resistance&#xD;
      mechanisms during anti-EGFR (epidermal growth factor receptor) treatment is of great&#xD;
      interest, as evidenced by the recent journal published by Corcoran in the prestigious New&#xD;
      England Journal of Medicine.&#xD;
&#xD;
      EmutRAS is one of the first studies that will specifically and prospectively evaluate the RAS&#xD;
      mutational switch and its impact on the efficiency of the 1st line processing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is the Detection of RAS mutational (rat sarcoma viral oncogene&#xD;
      homolog) &quot;switch&quot; in circulating DNA by Intplex® test in mCRC (metastatic colorectal cancer)&#xD;
      patients treated with antibody anti-EGFR (epidermal growth factor receptor), cetuximab or&#xD;
      panitumumab in first line.&#xD;
&#xD;
      The treatment and these modalities will be decided by the investigator.&#xD;
&#xD;
      The study is based on blood sampling, the frequency of which is described below, rhythm of&#xD;
      plasma samples:&#xD;
&#xD;
      Inclusion after determination of wild status RAS tissues.&#xD;
&#xD;
      First sampling of 2 EDTA (ethylenediaminetetraacetic acid) tubes, then at each tumour&#xD;
      evaluation during treatment with anti EGFR (epidermal growth facor receptor), every 4 cures.&#xD;
      At the end of treatment or after more than 36 treatment cures, a final sample will be taken.&#xD;
&#xD;
      No results of the samples will be communicated to the investigator, the sponsor will&#xD;
      centralize these results for the final analysis of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probability of obtaining a positive test, i.e. RAS status mutated by the Intplex® test, among the patients determined RAS mutated by the tissue test</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of obtaining a negative test, i.e. wild RAS status by the Intplex® test among patients determined wild RAS by the tissue test</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of obtaining a positive test, i.e. BRAF status mutated by the Intplex® test, among the patients determined BRAF mutated by the tissue test</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of obtaining a negative test, i.e. wild BRAF status by Intplex® test among patients determined wild BRAF by tissue test.compared to the pre-treatment tissue test</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a BRAF mutation under anti-EGFR therapy</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From baseline to the database cutoff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From baseline to the database cutoff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the following criterion: total concentration of circulating DNA</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the following criterion: integrity index</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the following criterion: concentration of mutated alleles</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the following criterion: frequency of mutated alleles</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>From baseline to the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Intplex test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In vitro diagnostic device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intplex test</intervention_name>
    <description>Blood sample at each tumor assessment</description>
    <arm_group_label>Intplex test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically confirmed metastatic colorectal cancer&#xD;
&#xD;
          -  Patient treated in the first line by one of the treatments below and according to a&#xD;
             bi-monthly schema for cetuximab: FOLFIRI (elvorin + 5 Fluorouracil + irinotecan) ou&#xD;
             FOLFOX (elvorin + 5 Fluorouracil + oxalplatin) + Cetuximab* (Erbitux) ; FOLFIRI ou&#xD;
             FOLFOX + Panitumumab (Vectibix); FOLFIRINOX ou FOLFOXIRI ((elvorin + 5 Fluorouracil +&#xD;
             oxaliplatin + irinotecan) + Cetuximab* (Erbitux); FOLFIRINOX ou FOLFOXIRI +&#xD;
             Panitumumab (Vectibix) For patient treated cetuximab administration will be bi-monthly&#xD;
&#xD;
          -  Patient with at least one evaluable metastatic target according to RECIST 1.1&#xD;
             (Response Evaluation Criteria in Solid Tumors)&#xD;
&#xD;
          -  Wild RAS (rat sarcoma viral oncogene homolog) status detected by standard tissue test,&#xD;
             on primary tumor and / or metastasis&#xD;
&#xD;
          -  Wild BRAF (murine sarcoma viral oncogene homolog B) status detected by standard tissue&#xD;
             test, on primary tumor and / or metastasis&#xD;
&#xD;
          -  Man or woman&gt; 18 years old&#xD;
&#xD;
          -  Signed informed consent before any specific procedure to study&#xD;
&#xD;
          -  Patient affiliated to the social security or equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with an anti-EGFR (epidermal growth factor receptor)&#xD;
&#xD;
          -  Patient with a multifocal primary tumor&#xD;
&#xD;
          -  RAS (rat sarcoma viral oncogene homolog) status mutated or not detectable on tissue&#xD;
             analysis&#xD;
&#xD;
          -  BRAF (murine sarcoma viral oncogene homolog B) status mutated or undetectable on&#xD;
             tissue analysis&#xD;
&#xD;
          -  Patient receiving adjuvant chemotherapy or radiotherapy within &lt;14 days&#xD;
&#xD;
          -  History of other cancer in the last 5 years (except in-situ carcinoma of the cervix&#xD;
             and cutaneous carcinoma excluding melanoma treated optimally)&#xD;
&#xD;
          -  Blood transfusion (whole blood, red blood cell, platelets...) in the previous week&#xD;
&#xD;
          -  Patients with psychological, familial, sociological or geographic conditions&#xD;
             potentially not favorable to the good observance of the study protocol and the&#xD;
             follow-up&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
        Participation in another interventional clinical trial - biomedical research (therapeutic&#xD;
        strategy type) is not excluded provided that it is use an Anti-EGFR with a AMM (marketing&#xD;
        authorization), (Cetuximab - Panitumumab) with a dose and a standard administration rhythm&#xD;
        (according to the AMM).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thibault MAZARD, Dr</last_name>
    <phone>0467613000</phone>
    <phone_ext>+33</phone_ext>
    <email>thibault.mazard@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BLEUSE Jean-pierre</last_name>
      <phone>00467613102</phone>
      <email>jean-pierre.bleuse@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc YCHOU, MD, PhD</last_name>
      <phone>+33467613102</phone>
      <email>marc.ychou@icm.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Detection of the emergence of RAS mutations</keyword>
  <keyword>Circulating DNA in patients</keyword>
  <keyword>Treatment with anti-EGFR therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

